Sign In
Buy EYEN
$7.56
+0 (+0%)
At Close: Jan 16, 2026
On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet
Eyenovia to discontinue late-stage study for eye drug
07:07am, Friday, 15'th Nov 2024
Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.
Eyenovia Provides Update on Phase 3 CHAPERONE Study
07:00am, Friday, 15'th Nov 2024
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript
10:42pm, Tuesday, 12'th Nov 2024
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Pa
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
06:51pm, Tuesday, 12'th Nov 2024
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago.
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
07:00am, Thursday, 07'th Nov 2024
Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
07:00am, Wednesday, 16'th Oct 2024
Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ocular
Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now
10:56am, Monday, 14'th Oct 2024
Eyenovia (EYEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
07:00am, Tuesday, 01'st Oct 2024
The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 The Gen-2 Optejet is designed for an optimized use
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
08:30am, Friday, 27'th Sep 2024
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two FDA-approved products and a late-stage asset
New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol's prescribing information New market research shows strong interest from ophthalmic surgeons fol
TAIPEI , Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new opht
Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer
07:00am, Tuesday, 03'rd Sep 2024
Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition Current CFO, John Gandolfo, to remain with the Company through November as part of plan
Eyenovia Announces Closing of Public Offering
11:42am, Friday, 23'rd Aug 2024
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offeri
